BioNTech's Long Goodbye: Founders Exit as Pipeline Questions Mount
Published on 09/11/2026 at 13:10 | Editorial boerse-global.de
BioNTech is navigating a transition that runs deeper than a trimmed revenue forecast. The company's true inflection point lies in an announced leadership handover — one that has drawn far less scrutiny than it deserves.
Ugur Sahin, co-founder and the public face of BioNTech since the pandemic, will pass the CEO reins to Guido Oelkers no later than February 1, 2027. Oelkers joins from Swedish specialty pharma group Sobi. Sahin and co-founder Özlem Türeci are set to depart for a new, independent mRNA venture by the end of 2026 — a double exit that removes precisely the pair who turned a niche biotech into a multi-billion-dollar vaccine powerhouse.
The timing of this succession overlaps conspicuously with Sahin's share disposals. In early September, he sold 76,500 shares under a Rule 10b5-1 trading plan established in June, followed days later by another 73,000 shares — a combined value of roughly $15 million. A separate filing noted a sale of 37,000 shares. Such automated plans are set well in advance and execute regardless of daily news flow, so they carry no formal alarm signal. Even so, the broader picture — a founder retreating both operationally and financially — fits a pattern.
A Pipeline That Still Carries the Story
The more consequential question is whether an outsider unfamiliar with BioNTech's inner workings can drive the transformation from vaccine maker to oncology company as forcefully as the founders have.
Oelkers brings specialty pharma experience from Sobi, but he inherits a delicate balancing act: a shrinking Comirnaty franchise on one side, an unproven oncology portfolio on the other.
Should investors sell immediately? Or is it worth buying BioNTech?
Late August brought a sharp setback. BioNTech and partner Genentech had to halt a Phase 2 trial of autogene cevumeran in ctDNA-positive stage II/III colorectal cancer after an independent data monitoring committee found a numerical imbalance in overall survival between treatment arms. No new safety signals emerged, and the committee concluded that continuing the study would be unlikely to change the efficacy readout. The separate IMcode003 trial of autogene cevumeran in ductal pancreatic cancer, run with Roche subsidiary Genentech, remains unaffected and continues as planned.
On the positive side of the ledger sits pumitamig, which showed response rates of up to 72.7% in first data for non-small cell lung cancer when combined with chemotherapy. Starting September 12, BioNTech will present fresh data at the IASLC World Conference on Lung Cancer in Seoul — including a novel combination of pumitamig and elfetabart drozuntecan, plus updated survival data from the Phase 3 PRESERVE-003 study of gotistobart.
Those readouts could determine whether the incoming CEO takes over a company with an intact oncology story or one forced to push its growth promises back yet again.
Analyst Caution and a Stock Without Direction
BMO Capital downgraded BioNTech from Outperform to Market Perform on September 8, cutting its price target to $105 from $128. The broker cited weaker global demand for Covid vaccines and inventory destocking in Germany — the same forces behind the company's reduced full-year 2026 revenue guidance of EUR 1.6 to 1.9 billion, down from a prior range of EUR 2.0 to 2.3 billion.
The equity reflects the uncertainty. At EUR 84.00, the stock sits just above the previous close of EUR 83.05, but remains 21% below its 52-week high of EUR 105.80. A 6.0% decline over the past seven trading sessions underscores that the market is eyeing the mix of leadership change, trial setback, and a weakening vaccine business with skepticism. On a monthly basis, however, the shares are up 4.7%, and at EUR 84.25 they trade near both the 50-day average of EUR 84.09 and the 200-day average of EUR 84.17 — a picture of directionlessness that mirrors the conflicting news flow.
What investors should not read into Sahin's sales is a loss of confidence; the scheduled plan offers no basis for that conclusion. The real question is whether the oncology pipeline underpinning BioNTech's long-term story still has enough substance after the colorectal cancer failure. The ongoing pancreatic cancer trial with Genentech provides at least one open test — one whose result is not yet known.
For now, the open questions outweigh the certainties. A founding team stepping back while pivotal studies stumble and core forecasts are cut is not a combination that signals stability. Yet the substance remains striking: 14 ongoing registration trials, a war chest of EUR 16.6 billion, and the Seoul lung cancer data offering a near-term catalyst that could bring clarity. Whether BioNTech completes the leap from pandemic winner to durable oncology player — or whether the handover becomes the break that finally stalls its momentum — will be decided in the months ahead.
Ad
BioNTech Stock: New Analysis - 11 September
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
